# SurgiMend® vs. Strattice™ in Direct to Implant Breast Reconstruction- A Prospective Randomized Trial

> **NCT02521623** · NA · COMPLETED · sponsor: **Aarhus University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DEVICE:** SurgiMend® Acellular Dermal Matrix
- **DEVICE:** Strattice™ Acellular Dermal Matrix

## Key facts

- **NCT ID:** NCT02521623
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521623, "SurgiMend® vs. Strattice™ in Direct to Implant Breast Reconstruction- A Prospective Randomized Trial". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02521623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*